90results about How to "Treatment stable" patented technology

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Disclosed is a biological desulfurization apparatus including a reaction tower 1 into which biogas generated by anaerobic fermentation of organic waste is to be introduced, a carrier-packed layer 2a, 2b arranged in the reaction tower and provided with a carrier to which microorganisms have adhered, an air feeding pipe 3 that mixes air into a lower part of the reaction tower, and a sprinkling mechanism 7 that sprinkles water on an upper part of the reaction tower, wherein the carrier-packed layer is arranged in two or more stages.

The present invention provides parathyroid hormone and/or parathyroid hormone-related protein analogs, compositions thereof and methods thereto.

The invention provides a process and apparatus for treating water, which can be stably operated with high efficiency over a long period of time. The apparatus has a grounding electrode and a pair of applying electrodes connected to a DC voltage source through a register and first and second high-frequency switches which are controlled by a high-frequency switching commander circuit, to convert DC voltage from the DC voltage source to AC voltage to be fed to the applying electrodes. The high-frequency switching commander circuit is connected to a first high-frequency oscillation circuit connected to a control circuit which is controlled by a second high-frequency oscillation circuit, to provide a signal changing randomly in frequency as output signal from the first high-frequency oscillation circuit. The second high-frequency oscillation circuit also controls a flip-flop circuit connected to the first high-frequency oscillation circuit, to add acutely and momentary frequency fluctuating portions in randomly frequency changing signal from the first oscillation circuit.

A solid-state VC sodium injection for treating the diseases caused by VC difficiency is prepared from VC sodium, VC and the pharmacologically acceptable additives.

A process recipe is controlled by processing reflection interference light on the surface of a wafer with a signal and etching is carried out by suppressing an increase in the surface roughness of the wafer during etching. That is, a dry etching method for use in a dry etching system comprising means of treating a sample by generating plasma in a vacuum process chamber and monitor means of monitoring the reflection interference light of the sample to be treated, the method comprising the step of detecting the spectrum of reflection interference light on the surface of the sample to be treated, the step of obtaining a residual from curve fit between a theoretical value estimated from the film reflection model of the surface of the wafer and the spectrum of reflection interference light, and the step of judging whether the residual from the curve fit falls within a predetermined value.

The present invention is to provide a hemodialysis system optimized, for example, to suppress fluctuations in blood pressure in accordance with differences between individual patients. This system isconfigured to include: a blood-related information acquiring means for acquiring blood flow information in a hemodialysis blood circuit, and patient biometric information such as peripheral vascular resistance information, blood pressure information, facial information, body movement information, temperature information, and humidity information; an individual difference information management means for acquiring and managing patient individual-difference information from the blood-related information; and an optimized dialysis means for performing dialysis treatment optimized for the patient,on the basis of the patient individual-difference information.

The invention discloses a medicine for treating kidney stone and gall-stone, according to a calculus formation pathology and a pharmacological experiment formula, the medicine of the invention is prepared by arbutin, desmodium, lichee nucleus, longan nucleus, common fenugreek seed, gecko, pig iron cinder, gynostemma pentaphylla, plantago, Orthosiphon Stamineus, Caulis aristolochiae manshuriensis, bletilla rhizome, magnolia cortex and sweetleaf tea. The materials are natural-green, safe and reliable. A traditional Chinese medicine toxin expelling therapy is used. The medicine is capable of releasing spasm, relieving pain, smoothing skin, sterilizing, softening hardness and dissipating binds, soothing liver and resolving depression, clearing heat and dispersing stagnate, rectifying qi, disinhibiting urine and freeing strangury and benifiting openheartedness, the medicine can directly act on nidus, an organic matter is subjected to releasing, dissolving and biological enzymatic hydrolysis, can comprehensively permeated in a core of the calculus, the calculus can be cracked, melted and dissolved layer by layer from outer part to inner part, and the waste liquid is excreted through human excretion tissue, and the damaged cells can be activated, the gland can be balanced, the organ vitality can be enhanced, the acid-base value of blood can be balanced, the calculus recurrence can be prevented, and the simultaneous treatment of principal and subordinate symptoms effect can be acted.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The invention discloses polyurethane and a preparation method of polyurethane and ROS (Reactive Oxygen Species)-responsive polyurethane drug-loading micelles. The method comprises the following steps:dissolving hydrophobic drugs and prepared polyurethane solids into a dimethyl sulfoxide solution, slowly dropwise adding the solution into deionized water while intense stirring, continuously stirring, filling in a dialysis bag of MW=3500 after stirring completion, dialyzing for two days, dialyzing to remove non-entrapped hydrophobic drugs; and finally obtaining the stable ROS-responsive polyurethane drug-loading micelles with near-infrared light photothermal therapy and drug synergism. The preparation method of the polyurethane drug-loading micelles disclosed by the invention is simple and novel, and compared with the novel photosensitizer-ruthenium complex for photothermal therapy and the reported drug carrier before, the carrier disclosed by the invention is stable before subjected tonear-infrared stimulation when bonded into the main polymer chain, and effective release of the drugs and treatment of tumor cells can be realized once the carrier is initiated.

Anaerobic treatment of water is performed under anaerobic conditions with a biofilm formed on a surface of a fluid non-biological carrier in a reaction vessel. Stable high-load treatment is performed by preventing the blockage of the reaction vessel caused by the flotation and adhesion of the non-biological carrier in the reaction vessel and effectively recovering the settleability of the carrier floating owing to adhering air bubbles by simple means. A reaction vessel is charged with a fluid non-biological carrier having a size in the range of 1.0 to 5.0 mm and a settling velocity in the range of 200 to 500 m/h. Part of the carrier that has floated and flowed out of the reaction vessel is fed downward through a pipe having a vertical height of 50 cm or more so as to remove air bubbles adhering to the carrier and is returned to the reaction vessel.